SZU General Hospital

Yonghui Li
SZU General Hospital
Molecular Biology and Biochemistry
Director of Central Laboratory
简介:


BIOGRAPHICAL SKETCH


NAME: Yonghui Li


POSITION TITLE: Director of Central Laboratory, Shenzhen University General Hospital


EDUCATION/TRAINING

INSTITUTION AND LOCATION

DEGREE

COMLETION DATE

FIELD OF STUDY

Mount Sinai School of Medicine, New York, N.Y.

Post-doctoral fellow

2008

Molecular Biology and Biochemistry

 

 

 

 

Beijing Institute of Radiation Medicine, Academy of Military Medical Sciences, Beijing, China

Ph.D.

2003

Molecular Biology and Biochemistry

 

 

 

 

Department of Biology, Henan Normal University, Xinxiang, Henan Province, China.

Master Degree

2000

Biology

 

A. Personal statement

Major research interests: The structure and function of the AML-ETO splicing complex; genome instability and the function of the THAP10 protein; the mechanisms of degradation of the fusion proteins AML1-ETO and AML1-ETO9a; proteomic analyses of AML1, AML1-ETO and AML1-ETO9a target genes; epigenetic analyses of AML stem-cell development; M6A modification in RNA splicing; the mechanisms of HDACi in t(8;21) AML; and genome instability in the context of t(8;21) AML and m6A modification.

 

B. Positions and honors

Positions

2019: Professor, Department of Hematology, The General Hospital of PLA, Beijing

2017: PI, State Key Laboratory of Kidney Disease, Beijing

2016: General Secretary of the Precision Medicine Society of Hematology, Chinese Research Hospital Association

2014: Associate professor, Department of Hematology, The General Hospital of PLA, Beijing.

 

C. Representative publications (selected publications in recent five years   5-10篇)

1.Chen G, Liu A, Xu Y, Gao L, Jiang M, Li Y, Lv N, Zhou L, Wang L, Yu L*, Li Y*. The RUNX1-ETO fusion protein trans-activates c-KIT expression by recruiting histone acetyltransferase P300 on its promoter. FEBS J. 2019 Mar;286(5):901-912. (Corresponding Author)

2.Li Y, Ning Q, Shi J, Chen Y, Jiang M, Gao L, Huang W, Jing Y, Huang S, Liu A, Hu Z, Liu D, Wang L, Nervi C, Dai Y, Zhang MQ, Yu L*. A novel epigenetic AML1-ETO/THAP10/miR-383 mini-circuitry contributes to t(8;21) leukaemogenesis. EMBO Mol Med, 2017, 9(7):933-949 (First Author)

3.Liang Y, Zhou H, Yao Y, Deng A, Wang Z, Gao B, Zhou M, Cui Y, Wang L, Zhou L, Wang B, Wang L, Liu A, Qiu L, Qian K, Lu Y, Deng W, Zheng X, Han Z, Li Y*, Sun J*. 12-O-tetradecanoylphorbol-13-acetate (TPA) increases murine intestinal crypt stem cell survival following radiation injury. Oncotarget, 2017, 8(28):45566-45576 (Corresponding Author)

4.Fu L, Shi J, Liu A, Zhou L, Jiang M, Fu H, Xu K, Li D, Deng A, Zhang Q, Pang Y, Guo Y, Hu K, Zhou J, Wang Y, Huang W, Jing Y, Dou L, Wang L, Xu K, Ke X, Nervi C, Li Y,* Yu L*. A minicircuitry of microRNA-9-1 and RUNX1-RUNX1T1 contributes to leukemogenesis in t(8;21) acute myeloid leukemia, Int J Cancer, 2017, Feb 1. 140(3):653-661. (Corresponding Author)

5.Zhou L, Fu L, Lv N, Chen XS, Liu J, Li Y, Xu QY, Huang S, Zhang XD, Dou LP, Wang LL, Li YH*, Yu L*. A minicircuitry comprised of microRNA-9 and SIRT1 contributes to leukemogenesis in t(8;21) acute myeloid leukemia, Eur Rev Med Pharmacol Sci, 2017 Feb;21(4):786-794. (Corresponding Author)

6.B Wang, Y Liu, L Wang, N Lv, Y Xu, Y Xu, X Wang, Z Xuan, Y Jing, H Li, X Jin, A Deng, L Wang, X Gao, L Dou, J Liang, C Chen, Y Li*, L Yu*. Mutational spectrum and risk stratification of intermediate-risk acute myeloid leukemia patients based on next-generation sequencing, Oncogarget, 2016, 7(22):32065-78.(Corresponding Author)

7.Chen Z, Tan L, Wang S, Zhang Y, Li Y*. Sensitive colorimetric detection of K(I) using catalytically active gold nanoparticles triggered signal amplification. Biosens Bioelectron, 2016, 79:749-757. (Corresponding Author)

8.Li D, Wang L, Zhu H, Dou L, Liu D, Fu L, Ma C, Ma X, Yao Y, Zhou L, Wang Q, Wang L, Zhao Y, Jing Y, Wang L, Li Y*. Yu L*. Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation in Intermediate-Risk Acute Myeloid Leukemia Adult Patients in First Complete Remission: A Meta-Analysis of Prospective Studies. PLoS One. 2015 Jul 21;10(7):e0132620. (Corresponding Author)

9.Fu L, Huang W, Jing Y, Jiang M, Zhao Y, Shi J, Huang S, Xue X, Zhang Q, Tang J, Dou L, Wang L, Nervi C, Li Y*, Yu L*. AML1/ETO triggers epigenetic activation of EGR1 inducing apoptosis in t(8;21) acute myeloid leukemia. FEBS J. 2014, 281:1123-31. (Corresponding Author)

10.Yonghui Li, Li Gao, Xufeng Luo, Lili Wang, Xiaoning Gao, Wei Wang, Junzhong Sun, Liping Dou, Jingxin Li, Chengwang Xu, Lixin Wang, Minhang Zhou, Mengmeng Jiang, Jihao Zhou, Michael A. Caligiuri, Clara Nervi, Clara D. Bloomfield, Guido Marcucci*, and Yu L*. Epigenetic Silencing of microRNA-193a Contributes to Leukemogenesis in t(8;21) Acute Myeloid Leukemia by Activating the PTEN/PI3K Signal Pathway. Blood, 2013,121(3):499-509. (First Author)

D. Research support

Ongoing projects (RMB)

1,Beijing Natural Science Foundation Project (2010979). Anti-apoptosis mechanisms of THAP10/EZH2/C-KIT in t(8;21) acute myeloid leukemia. Principal Investigator. Jan. 2020-Dec. 2023, RMB 200,000

 

2, Chinese National Natural Science Foundation Project (81870134). Mechanisms of THAP10/EZH2/C-KIT axis in t(8;21) acute myeloid leukemia. Principal Investigator. Jan. 2019-Dec. 2022, RMB 600,000

 

3, Chinese National Natural Science Foundation Project (81570137). Epigenetic mechanisms of alternative splicing of variant transcript AML-ETO9a in t(8;21) acute myeloid leukemia. Principal Investigator. Jan. 2016-Dec. 2019, RMB 720,000

 

4, Key Project of Beijing Natural Science Foundation (7151009). The regulation mechanisms of splicing of variant transcript AML-ETO9a in t(8;21) acute myeloid leukemia. Principal Investigator. Jan. 2015-Dec. 2018, RMB 6520,000

 

5, Chinese National Natural Science Foundation Project (81370635). Epigenetic silencing of THAP10 contributes to leukemogenesis of t(8;21) acute myeloid leukemia. Principal Investigator. Jan. 2014-Dec. 2017, RMB 700,000

 

6, Chinese postdoctoral scholarship foundation. Study on mechanism of miR-193a in acute myeloid leukemia. Principal Investigator, Jan. 2010-Dec. 2011, RMB 30000

 

7, Chinese National Natural Science Foundation Project (30470676). The proapoptosis role of THAP11 and its mechanism. Principal Investigator. Jan. 2005-Dec. 2007, RMB 230,000

 

8, Chinese National Natural Science Foundation Project (30371596). The role of hepatopoietin (HPO) in invasiveness of hepatocellular carcinoma. Principal Investigator. Jan. 2004-Dec. 2006, RMB 210,000

 

9, Chinese National Natural Science Foundation Project (30370525). The mechanisms of biosynthesis of aromatic amino acid. Principal Investigator. Jan. 2004-Dec. 2006, RMB 210,000

 

10,The innovation foundation of Academy of Military Medical Sciences. The proapoptosis mechanism of THAP11. Principal Investigator. Mar. 2005-Mar. 2007. RMB 30,000

 

11, National Basic Research Program (“973”)(2002CB513100). The role and mechanism of newly cell stimuli in invasiveness of hepatocellular carcinoma. Co-investigator. Oct. 2003-Oct. 2008, RMB 3,000,000